Latest Kaiser Health News Stories
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers — middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
“If it gets signed by this governor, it’s going to send shock waves throughout the country,” one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
The new law will help people with chronic conditions that require multiple prescriptions cut down on their shuttles to the drug store and could improve adherence to their drugs.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.